NeuroSigma, Inc. Release: Positive Results Reported for Phase I Clinical Trial at University of California, Los Angeles (UCLA) for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
5/21/2013 9:55:08 AM
More...
|
NeuroSigma, Inc. Receives Health Canada Approval for Its Monarch eTNS System
5/2/2013 7:45:45 AM
More...
|
NeuroSigma, Inc. Release: Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD
4/19/2013 8:46:18 AM
More...
|
NeuroSigma, Inc. Release: Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD
4/18/2013 9:30:53 AM
More...
|
NeuroSigma, Inc. Release: External Trigeminal Nerve Stimulation (eTNS) for Refractory Status Epilepticus
3/25/2013 9:32:09 AM
More...
|
NeuroSigma, Inc. Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
2/11/2013 6:40:54 AM
More...
|
NeuroSigma, Inc. Awarded Fast Track SBIR Grant by the National Institutes of Health (NIH) for Development of Implantable sTNS System for Drug Resistant Epilepsy
2/4/2013 9:50:59 AM
More...
|
NeuroSigma, Inc. Announces Publication of Randomized Controlled Trial of eTNS for Treatment of Drug Resistant Epilepsy in the Leading Journal, Neurology®
1/31/2013 8:38:57 AM
More...
|
NeuroSigma, Inc. Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
1/22/2013 9:49:23 AM
More...
|
NeuroSigma, Inc.'s Monarch eTNS System to be Unveiled in London
9/25/2012 10:04:36 AM
More...
|
|